Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials (Q33832656)

29 July 2017

1 reference

title

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials (English)

1 reference

29 July 2017

Senderowicz AM

1

1 reference

29 July 2017

publication date

1 January 1999

1 reference

Investigational New Drugs

29 July 2017

published in

1 reference

29 July 2017

volume

17

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

313-320

1 reference

The regulation of E2F by pRB-family proteins

29 July 2017

cites work

1 reference

12 December 2020

Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer

1 reference

12 December 2020

Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.

1 reference

12 December 2020

Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol

1 reference

12 December 2020

Cyclin-dependent kinases: engines, clocks, and microprocessors

1 reference

12 December 2020

Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck

1 reference

12 December 2020

Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells

1 reference

12 December 2020

Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells

1 reference

12 December 2020

Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells

1 reference

12 December 2020

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 reference

12 December 2020

High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers

1 reference

12 December 2020

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

12 December 2020

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

1 reference

12 December 2020

Cell cycle and cancer: critical events at the G1 restriction point.

1 reference

12 December 2020

Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities

1 reference

12 December 2020

Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target

1 reference

12 December 2020

The retinoblastoma protein and cell cycle control

1 reference

12 December 2020

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

1 reference

12 December 2020

Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells.

1 reference

12 December 2020

Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons

1 reference

12 December 2020

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

1 reference

12 December 2020

Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts

1 reference

12 December 2020

Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity

1 reference

12 December 2020

In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer

1 reference

12 December 2020

Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis

1 reference

12 December 2020

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

1 reference

12 December 2020

Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line

1 reference

12 December 2020

Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration

1 reference

12 December 2020

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

12 December 2020

Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.

1 reference

12 December 2020

Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors

1 reference

12 December 2020

Cyclins and cyclin-dependent kinases: theme and variations

1 reference

12 December 2020

Identification of multiple cyclin subunits of human P-TEFb

1 reference

12 December 2020

PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro

1 reference

12 December 2020

Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase)

1 reference

12 December 2020

Clinical trials referral resource. Clinical trials of flavopiridol.

1 reference

12 December 2020

Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs).

1 reference

12 December 2020

Multiple molecular levels of cell cycle regulation

1 reference

12 December 2020

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

1 reference

12 December 2020

Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II

1 reference

12 December 2020

Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition

1 reference

12 December 2020

Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.

1 reference

12 December 2020

The role of RB in cell cycle control

1 reference

12 December 2020

Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver

1 reference

12 December 2020

1 reference

12 December 2020

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

1 reference

12 December 2020

Control of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases.

1 reference

12 December 2020

Human cyclin K, a novel RNA polymerase II-associated cyclin possessing both carboxy-terminal domain kinase and Cdk-activating kinase activity

1 reference

12 December 2020

A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA

1 reference

12 December 2020

Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol

1 reference

12 December 2020

The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006353008903

1 reference

Dimensions Publication ID

29 July 2017

1039150315

0 references

1 reference